Jon Mares, DO
Nephrology · Covington, LANPI 1023375300
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $93,465 of the $102,543 with a category attached, or 91.1%. Bayer accounts for 98.1% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2022 at $73,112 and has fallen 98.5% since, to $1,128 in 2025. Among nephrology clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 168 payments — averaging $610.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$101K
- AstraZeneca$690
- Amgen$337
- OPKO Pharmaceuticals, LLC$152
- Novo Nordisk$129
- Mallinckrodt Hospital Products Inc.$125
- plus $545 from 8 others
What the payments were for
- Speaking & faculty fees$93,46591%
- Travel & lodging$2,2042%
- Food & beverage$6,6667%
- Education$2080%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 119 | $100,565 |
| AstraZeneca(2 entities) | 17 | $690 |
| Amgen(2 entities) | 10 | $337 |
| OPKO Pharmaceuticals, LLC | 3 | $152 |
| Novo Nordisk | 1 | $129 |
| Mallinckrodt Hospital Products Inc. | 1 | $125 |
| Aurinia Pharma U.S., Inc. | 2 | $113 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $100 |
| Daiichi Sankyo Inc. | 5 | $86 |
| Sanofi | 1 | $85 |
| Otsuka America Pharmaceutical, Inc. | 3 | $59 |
| Vifor Pharma, Inc. | 2 | $37 |
| Calliditas Therapeutics US Inc. | 2 | $34 |
| Boehringer Ingelheim | 1 | $30 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$102,543 in reported general payments places this provider in the 95th percentile of 206 nephrology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Amlodipine Besylate | 20 | $225 |
| Olmesartan Medoxomil | 13 | $152 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Covington
- David PowersCovington$35K
- Peter vanCovington$8K
- Imran ShujaCovington$5K
- Sreedhara AllaShreveport$722K
- Anthony BlalockLafayette$350K
- Juan Carlos VelezNew Orleans$282K
- Jones SamuelBaton Rouge$207K
- Raja ZabanehShreveport$57K
- Michael TouchyNew Orleans$56K
- Kenneth AbreoShreveport$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.